GLP-1 Agonists for Adolescent Obesity: What the STEP TEENS Data Actually Shows

Why Childhood Obesity Cannot Wait for Adulthood

The conventional medical wisdom once held that pediatric obesity was a cosmetic or behavioral problem that children would "grow out of." That view has been comprehensively dismantled by longitudinal cohort studies. The Bogalusa Heart Study, tracking over 14,000 participants from childhood into adulthood, demonstrated that atherosclerotic lesions begin forming in the coronary arteries and aorta before age 10 in children with obesity — lesions that mirror those seen in middle-aged adults with established cardiovascular disease.

The physiological cascade unfolds early and is self-reinforcing. Excess adiposity drives systemic insulin resistance, which elevates hepatic glucose output, promotes visceral fat accumulation, and dysregulates adipokine secretion — including leptin resistance that further impairs satiety signaling. By adolescence, many children with severe obesity have already developed non-alcoholic fatty liver disease (NAFLD), hypertension, dyslipidemia, obstructive sleep apnea, polycystic ovarian syndrome (PCOS), and — increasingly — type 2 diabetes.

Perhaps most importantly, childhood obesity tracks strongly into adulthood. A landmark 2017 meta-analysis in NEJM found that obese children aged 6–11 had a 55% probability of being obese adults, rising to 80% for obese teenagers. This "tracking" effect means that interventions in adolescence are not just treating an acute condition — they are potentially interrupting a decades-long disease trajectory.

The STEP TEENS Trial: What the Data Actually Shows

The pivotal evidence for semaglutide in adolescents comes from the STEP TEENS trial (NCT04102189), published in the New England Journal of Medicine in January 2023. This was a 68-week, randomized, double-blind, placebo-controlled trial conducted across 21 sites in nine countries.

Trial Design and Population

STEP TEENS enrolled 201 adolescents aged 12–17 with obesity (BMI ≥95th percentile for age and sex) or overweight (BMI ≥85th percentile) with at least one weight-related comorbidity. Participants were randomized 2:1 to semaglutide 2.4 mg subcutaneously once weekly or matching placebo. All participants received lifestyle counseling throughout.

The trial included a dose-escalation period: participants began at 0.25 mg/week and escalated over 16 weeks to the maximum 2.4 mg maintenance dose — the same protocol used in adults.

Primary Endpoints and Results

The co-primary endpoints were percentage change in BMI from baseline to week 68, and the proportion of participants achieving ≥5% weight reduction. The results were striking:

• BMI reduction: −16.1% in the semaglutide group vs. +0.6% in placebo (treatment difference: −16.7 percentage points; 95% CI −20.3 to −13.2; P<0.001)
• ≥5% weight reduction: 73% of semaglutide participants vs. 18% in placebo
• ≥10% weight reduction: 62% vs. 8%
• ≥20% weight reduction: 37% vs. 3%
• Waist circumference: −9.0 cm in semaglutide vs. +1.0 cm in placebo
• Cardiometabolic markers: Significant improvements in HbA1c, fasting glucose, lipid panel, and blood pressure in the semaglutide group

Importantly, weight loss with semaglutide was associated with meaningful improvements in health-related quality of life (as measured by the Pediatric Quality of Life Inventory), including physical functioning, emotional well-being, and social functioning scores.

Tirzepatide in Pediatric Trials: The Next Frontier

Tirzepatide (Zepbound / Mounjaro), the dual GIP/GLP-1 receptor agonist from Eli Lilly, has demonstrated even larger weight reductions than semaglutide in adult populations. In the SURMOUNT-1 trial, adults on tirzepatide 15 mg achieved a mean weight reduction of 22.5% — the largest ever reported in a pharmacotherapy trial for obesity.

The SURMOUNT-PEDS trial is currently evaluating tirzepatide in adolescents aged 12–17 with obesity. As of mid-2024, enrollment is complete and results are anticipated in late 2024 or early 2025. If pediatric results mirror adult data — even partially — tirzepatide could offer an even more potent option for the subset of adolescents who need greater weight reduction to resolve severe comorbidities such as obstructive sleep apnea, severe NAFLD, or orthopedic complications.

Why Dual Agonism May Matter in Adolescents

The GIP (glucose-dependent insulinotropic polypeptide) receptor, targeted by tirzepatide in addition to GLP-1R, plays a role in bone metabolism and may also modulate adipose tissue differently than GLP-1 alone. Whether this translates to a better or worse safety profile in adolescents — particularly with respect to bone density — is one of the key questions SURMOUNT-PEDS is designed to answer. The dual mechanism also appears to reduce the frequency of nausea and vomiting compared to equivalent GLP-1 doses, which could be particularly relevant in a population at risk for eating disorders.

Safety Considerations Specific to Adolescents

The safety profile of GLP-1 agonists in adults is well-characterized. In adolescents, the same signals appear, but with additional developmental concerns that require careful monitoring and clinical judgment.

1. Growth and Linear Height

During puberty, the growth axis is highly active and sensitive to nutritional status. Severe caloric restriction can impair linear growth. In STEP TEENS, no significant difference in height velocity was observed between semaglutide and placebo groups over 68 weeks — a reassuring finding. However, the study was not powered to detect subtle effects on growth, and longer-term follow-up data are not yet available.

Clinicians should measure height and track growth velocity at every visit for adolescents on GLP-1 agonists, particularly for younger adolescents in early puberty where growth plates are still active.

2. Bone Density and Skeletal Development

Peak bone mass is largely achieved during adolescence. Rapid weight loss — regardless of mechanism — is associated with bone density reduction, particularly at the lumbar spine. In adult obesity studies, semaglutide has been associated with greater bone loss than expected from weight reduction alone, possibly due to reduced mechanical loading.

For adolescents, ensuring adequate calcium and vitamin D intake during treatment is essential. Consider baseline DEXA scanning in adolescents with additional risk factors for low bone density (e.g., low dairy/calcium intake, sedentary lifestyle, prior history of stress fractures).

3. Eating Disorder Risk

This is perhaps the most clinically nuanced concern. Adolescence is the peak period for eating disorder onset — particularly anorexia nervosa and bulimia nervosa — with onset most common in females aged 14–18. The appetite-suppressing effects of GLP-1 agonists could theoretically reinforce restrictive eating behaviors in susceptible individuals.

Conversely, binge-eating disorder and loss-of-control eating — which are more common in adolescents with obesity — may actually improve with GLP-1 therapy due to reduced hunger and food cue reactivity. The relationship between GLP-1 agonists and eating pathology in adolescents is complex and requires individualized assessment.

4. Gastrointestinal Side Effects and Nutritional Status

Nausea and vomiting are the most common adverse effects of semaglutide in adolescents, as in adults. In STEP TEENS, nausea occurred in 62% of the semaglutide group vs. 42% in placebo. Vomiting was reported in 42% vs. 18% respectively. Most GI events were mild to moderate and clustered around dose-escalation periods.

In adolescents who are still growing, sustained nausea and vomiting carry a greater risk of nutritional deficiency than in fully-grown adults. Adequate protein intake (≥1.2–1.5 g/kg/day) and micronutrient monitoring (iron, zinc, B12, folate) should be part of routine management. Involvement of a registered dietitian experienced in pediatric obesity is strongly recommended.

5. Pancreatitis and Gallbladder Disease

Acute pancreatitis — listed as a boxed warning for GLP-1 agonists — occurs at low but non-negligible rates. Rapid weight loss is also a well-established risk factor for gallstone formation and gallbladder disease. These risks exist in adolescents as in adults, and clinicians should maintain a low threshold for abdominal imaging in patients presenting with severe abdominal pain.

Evidence Table: GLP-1 Agents in Pediatric and Adolescent Populations

Prescribing Criteria and Clinical Decision Framework

FDA approval of semaglutide for adolescents sets minimum eligibility criteria, but clinical judgment requires more nuanced assessment. The following framework reflects current guidance from the American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline on Obesity in Children and Adolescents and the Obesity Medicine Association.

Lifestyle Intervention vs. Pharmacotherapy: Reframing the Debate

The 2023 AAP guidelines sparked controversy when they endorsed early pharmacotherapy for pediatric obesity — moving away from the "watch and wait" approach that characterized prior decades of clinical guidance. Critics argued that medications bypass the root causes of obesity. Proponents argued that lifestyle interventions alone have a decades-long record of modest, unsustained outcomes.

The evidence is unambiguous on efficacy. The most intensive lifestyle interventions — structured programs involving behavioral counseling, dietary modification, and supervised physical activity — achieve BMI reductions of 1–3% in randomized trials. Some meta-analyses show effects as small as 0.5 BMI units. The STEP TEENS trial achieved a 16.1% BMI reduction. These are not comparable magnitudes of effect.

The more sophisticated position — and the one reflected in current clinical guidelines — is that pharmacotherapy and lifestyle intervention are complementary, not competing. All participants in STEP TEENS received lifestyle counseling throughout the trial. The drug does not replace behavior change; it creates a metabolic environment in which behavior change becomes more achievable by reducing appetite dysregulation, food cue reactivity, and the compensatory metabolic slow-down that occurs with weight loss.

The practical question for clinicians is not "medication or lifestyle" but rather: which patients need pharmacological support in addition to lifestyle intervention to achieve the weight reduction necessary to prevent cardiometabolic damage? For adolescents with severe obesity and established comorbidities, the answer from the evidence is clear.

The Role of Bariatric Surgery

For adolescents with severe obesity (BMI ≥120% of the 95th percentile) who have not responded to less intensive treatments, metabolic bariatric surgery remains an option with robust long-term evidence. The Teen-LABS study demonstrated sustained weight loss and resolution of comorbidities (type 2 diabetes, hypertension) at 5-year follow-up after sleeve gastrectomy or Roux-en-Y gastric bypass.

GLP-1 agonists may serve as a pharmacological bridge for adolescents approaching surgical eligibility, or as an alternative for those who decline or are not candidates for surgery. They may also have a role in the post-bariatric setting to manage weight regain — though this indication has not been studied in adolescents.